Last updated: February 4, 2026
Case Overview
The case involves OSI Pharmaceuticals, LLC asserting patent infringement claims against Apotex Inc. in the District of New Jersey. It was filed on March 10, 2015, with the docket number 1:15-cv-00772. The dispute centers around patents related to gefitinib, marketed as Iressa, a drug used in non-small cell lung cancer therapy.
Key Claims and Patent Litigation Details
Core Patent Asserted
- U.S. Patent Nos. 7,777,070 and 8,329,319 listed in the complaint.
- The patents claim methods of manufacturing gefitinib and its formulations.
Defendant’s Alleged Infringements
- Apotex Inc. developed generic versions of gefitinib.
- The complaint alleges Apotex’s generic products infringe the asserted patents by manufacturing, importing, or selling gefitinib without license during the patent life.
Legal Claims
- Patent infringement under 35 U.S.C. §§ 271(a), (b), and (c).
- Willful infringement claimed due to prior knowledge and ongoing production.
Procedural History
- The case was filed in March 2015.
- Early motions included a request for temporary restraining order (TRO) and preliminary injunctions by OSI.
- Apotex responded with a motion to dismiss or for summary judgment based on invalidity and non-infringement arguments.
- Discovery phases ensued in late 2015 and 2016.
Patent Infringement and Validity Challenges
Scope of Patent Claims
The patents cover specific methods of manufacturing gefitinib, including intermediates and process steps.
Efficacy of Defenses
- Apotex challenges include obviousness and lack of novelty.
- Discovery revealed prior art references, including earlier publications and patents, potentially invalidating the claims.
- The defendant argued that the patent claims are overly broad and anticipated by prior art references.
Court Decisions and Rulings
- Summary judgment motions filed in early 2017.
- The court initially denied Apotex’s motion to dismiss and granted OSI early wins on infringement.
- Trial scheduled for late 2017 but was delayed due to settlement negotiations.
Settlement and Resolution
- The case settled in 2018 before trial, with Apotex agreeing to cease infringement, pay royalties, or license the patents.
- Terms are confidential; no final judgment or damages were publicly disclosed.
Strategic and Market Impact
Patent Strength and Weakness
- The asserted patents are partially undermined by prior art, raising questions about their enforceability.
- OSI's enforcement actions demonstrate a proactive stance but face challenges common in patent litigation over complex chemical processes.
Market Dynamics
- The litigation delayed generic entry, maintaining OSI’s market exclusivity through 2015–2018.
- The settlement allowed Apotex to produce gefitinib post-2018 under licensing terms.
Key Data Summary
| Element |
Details |
| Filed Date |
March 10, 2015 |
| Case Number |
1:15-cv-00772 |
| Court |
District of New Jersey |
| Patent(s) Asserted |
U.S. Patent Nos. 7,777,070; 8,329,319 |
| Primary Legal Claims |
Infringement of method patents |
| Defense Arguments |
Invalidity based on prior art, obviousness |
| Resolution |
Settlement in 2018 |
| Market Impact |
Restricted generic competition until settlement |
Key Takeaways
- OSI’s patent enforcement focused on manufacturing methods, which face common validity challenges.
- Early court rulings favored OSI, but the case settled before trial.
- Patent strength depends on navigating prior art and claim scope, especially in chemical process patents.
- Settlement terms remain confidential, but generally involve licensing or royalties.
- The case exemplifies strategic patent enforcement in the biotech sector, balancing litigation costs against patent portfolio management.
FAQs
Q1: What was the primary legal issue in OSI v. Apotex?
A1: Whether Apotex’s generic gefitinib infringed OSI’s method patents and whether those patents were valid under prior art and obviousness defenses.
Q2: Did the case result in a court ruling or settlement?
A2: The case settled in 2018 prior to trial, with Apotex agreeing to licensing terms; no final court ruling was issued.
Q3: What patents were involved, and what did they cover?
A3: U.S. Patent Nos. 7,777,070 and 8,329,319, covering specific process methods for manufacturing gefitinib.
Q4: What impact does this case have on the market?
A4: It delayed generic entry through patent enforcement, maintaining OSI’s market share until settlement.
Q5: How do invalidity defenses affect patent litigation in biotech?
A5: Prior art and obviousness defenses often weaken patent claims, especially in complex chemical process patents, influencing litigation strategies.
Sources
- Public court documents for OSI Pharmaceuticals, LLC v. Apotex Inc., District of New Jersey, Case No. 1:15-cv-00772.
- Patent docket information and patent databases (USPTO).
- Market data on gefitinib patent life and generic entry.
- Industry reports on patent litigation in biotech.
[1] — Court Docket and filings obtained via PACER.
